Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1358011 | 0.94 | CYP3A4 (0.37) | CYP3A4CHEK1 | |
| SCHEMBL1359499 | 0.94 | CYP3A4 (0.37) | CYP3A4CHEK1 | |
| SCHEMBL1358409 | 0.93 | ALDH1A1 (0.36) | CYP3A4 | |
| SCHEMBL1360029 | 0.93 | ALDH1A1 (0.36) | CYP3A4 | |
| SCHEMBL1359241 | 0.93 | ALDH1A1 (0.36) | CYP3A4 | |
| SCHEMBL1359329 | 0.88 | CYP3A4 (0.36) | CYP3A4 | |
| SCHEMBL1360377 | 0.88 | CHEK1 (0.34) | CYP3A4CHEK1 | |
| SCHEMBL1360367 | 0.87 | CYP3A4 (0.34) | CYP3A4 | |
| SCHEMBL1360041 | 0.87 | CYP3A4 (0.34) | CYP3A4 | |
| SCHEMBL1360027 | 0.87 | NPY5R (0.33) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2334662-A1 | PYRINE OR PYRAZINE DERIVATIVES FOR TREATING HCV | F. Hoffmann-La Roche AG (CH) | 2011-06-22 | — | — | EP | claimed |
| US-20100081658-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC | 2010-04-01 | — | — | US | claimed |
| WO-2010034671-A1 | PYRINE OR PYRAZINE DERIVATIVES FOR TREATING HCV | F. HOFFMANN-LA ROCHE AG (CH) | 2010-04-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081658-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, POLR2A, HCCS | CYP3A4 713/4885CHEK1 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.